) The Biochemistry and Biotechnology Facility (BBF) makes available to Fox Chase investigators three state-of-the-art services that are connected to each other in research applications. DNA Technology provides uniformly high quality DNA, RNA, and modified oligonucleotides, the assembly of designer genes, and mutation detection by our patented process. Because of quality control, oligonucleotides from BBF have never been a variable in the users' experiments. DNA Technology leads to new genes and proteins that are further supported by the Biotechnology services of BBF. These include protein expression, fermentation, purification of enzymes and peptides, phage-displayed antibodies, and HPLC applications. A new addition is the BIAcore biosensor with which protein-ligand interactions are now investigated effectively. Through BBF, translational research projects gain instant access to equipment, manpower, and expertise in cutting edge technologies, and new investigators can quickly get up to speed. With institutional and CCSG developmental funds, the BBF has extended the above research with modern Mass Spectrometry. Services include high sensitivity protein analysis and identification, partial peptide sequencing, characterization of post-translational modifications, DNA analysis, drug chemistry, and enzyme characterization. In the cell, post-translational modifications of the proteins and changes in the level of key proteins provide important mechanisms whereby cellular processes are controlled. This important area of cancer biology is currently best addressed by combining 2D gel electrophoresis with mass spectrometry. BBF is using these techniques to assist many research programs at FCCC, and proposes to achieve even higher efficacy in the next CCSG cycle. BBF services support 52 peer-review funded principal investigators in all 13 Programs in all three Divisions. The staff of BBF is thoroughly cross-trained to assist each other. Because of the readiness of instruments, manpower, and experience, the efficacy of the BBF is impossible in the settings of individual laboratories. The BBF staff make frequent contact with the Facility users to determine how the Facility can best serve them. This energetic style of operation stimulates scientific interactions and the dissemination of ideas. Many projects have facilitated the obtaining of new peer-review support, new collaborations, publications, and patents.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-40
Application #
6652204
Study Section
Project Start
2002-07-01
Project End
2003-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
40
Fiscal Year
2002
Total Cost
$196,218
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Mortazavi, S M J; Bevelacqua, J J; Fornalski, K W et al. (2018) Comments on ""Space: The Final Frontier-Research Relevant to Mars"". Health Phys 114:344-345
Esposito, Andrew C; Crawford, James; Sigurdson, Elin R et al. (2018) Omission of radiotherapy after breast conservation surgery in the postneoadjuvant setting. J Surg Res 221:49-57
Dong, Yanqun; Zaorsky, Nicholas G; Li, Tianyu et al. (2018) Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer. J Med Imaging Radiat Oncol 62:116-121
Ge, Yunhui; Borne, Elias; Stewart, Shannon et al. (2018) Simulations of the regulatory ACT domain of human phenylalanine hydroxylase (PAH) unveil its mechanism of phenylalanine binding. J Biol Chem 293:19532-19543
Chow, H Y; Dong, B; Valencia, C A et al. (2018) Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer. Nat Commun 9:3473
Egleston, Brian L; Pedraza, Omar; Wong, Yu-Ning et al. (2018) Temporal trends and characteristics of clinical trials for which only one racial or ethnic group is eligible. Contemp Clin Trials Commun 9:135-142
Golemis, Erica A; Scheet, Paul; Beck, Tim N et al. (2018) Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 32:868-902
Reese, Jennifer Barsky; Sorice, Kristen; Lepore, Stephen J et al. (2018) Patient-clinician communication about sexual health in breast cancer: A mixed-methods analysis of clinic dialogue. Patient Educ Couns :
Wagner, Jessica; Kline, C Leah; Zhou, Lanlan et al. (2018) Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. J Clin Invest 128:2325-2338
Araiza-Olivera, D; Feng, Y; Semenova, G et al. (2018) Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors. Oncogene 37:944-952

Showing the most recent 10 out of 1280 publications